Page 5 - Ib Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

INSIDE INFORMATION Launch of negotiation with main creditors Agreement with Global Tech Opportunities (GTO) to secure short term financing Mont-Saint-Guibert, Belgium, June 30, 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in the areas of innate immunity, inflammation and organ/function repair, today provides a financial update. BioSenic has obtained an official appointment of Yves Brulard to reach a negotiated agreement

Press ReleaseMedia Contacts:IB CommunicationsTel +44 (0)20 89434685immutep@ibcomms.agency Immutep granted United States patent for IMP761, a first-in-class agonist antibody targeting LAG-3 Sydney, Australia, June 21, 2023 - Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechno...

INSIDE INFORMATION Combining arsenic and a metal ion decreases dosage needed for therapeutic effects in preclinical chronic graft-versus-host disease and systemic sclerosis models ... | June 20, 2023

INSIDE INFORMATION Combining arsenic and a metal ion decreases dosage needed for therapeutic effects in preclinical chronic graft-versus-host disease and...

INSIDE INFORMATION Prior efficacy unmatched but excellent safety profile confirmed, timing of ALLOB administration for optimal bone repair to...